Menu
Close
Funded Projects

POISE Wisconsin: Primary and Oncology Integration for Survivorship Equity in Wisconsin

Awarded in 2024
Postdoctoral Grant
Updated Sep 29, 2025

At a Glance

There are more than 300,000 cancer survivors in Wisconsin, a number expected to rise significantly in the coming decade. Yet, cancer survivorship care remains fragmented—primary care providers (PCPs) often face challenges coordinating with oncology teams, resulting in unmet needs, poor communication and worse outcomes for underserved patients. This project, POISE Wisconsin, will conduct surveys and focus groups with PCPs across the state to identify multi-level barriers and facilitators to care coordination. Guided by Implementation Science frameworks and a health equity lens, the study will highlight the strategies and resources needed to integrate primary and oncology care in Wisconsin.

More Funded Projects

research icon: microscope and stethoscope
Postdoctoral Grant

Improve Diagnosis of Sepsis through Analysis of Fragmentation Patterns in Plasma Cell-free DNA

Awarded in 2024
Sepsis is a life-threatening condition that is difficult to diagnose quickly in critically ill patients. Current tests, such as microbial cultures, are slow and often lack sensitivity, delaying treatment and increasing risks. This project will develop computational methods to analyze cell-free DNA (cfDNA) fragmentation patterns in blood as a rapid, low-cost tool to detect sepsis and identify infection sites. By studying DNA released from damaged tissues, the research aims to distinguish sepsis from non-infectious inflammation and monitor patient response to treatment.
research icon: microscope and stethoscope
Postdoctoral Grant

Fabp7 Silencing as a Strategy to Treat Mutant GFAP-induced Neuroinflammation in Alexander’s Disease

Awarded in 2024
Alexander disease (AxD) is a rare devastating neurodegenerative disorder caused by mutations in the GFAP gene, leading to toxic protein buildup in astrocytes, severe inflammation and progressive neurological decline. There are no current treatments. This project investigates the role of fatty acid binding protein 7 (FABP7), which is abnormally elevated in AxD and may drive harmful astrocyte-mediated inflammation. Using an innovative viral approach to silence FABP7 in a mouse model of AxD, the study will test whether reducing FABP7 expression can lower inflammation, decrease disese pathology and improve outcomes.